Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04591483 · ClinicalTrials.gov registry record
Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4
A clinical trial of Stargardt-like Macular Dystrophy, sponsored by National Eye Institute (NEI).
- Recruiting
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT04591483 is a study of Stargardt-like Macular Dystrophy that is actively recruiting participants, run by National Eye Institute (NEI). The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04591483, a study of Stargardt-like Macular Dystrophy, is actively recruiting participants, sponsored by National Eye Institute (NEI).
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: STDG3 is an inherited eye disease. Currently there is no treatment for STDG3. Past studies of STDG3 have largely looked at members of large families at a single time point. Researchers want to learn more about the disease at an individual level. Objective: To understand the natural history of changes in the retina that occur in people with STDG3. Eligibility: People ages 10 and older with STDG3 due to a variant in the ELOVL4 gene. Design: Participants will have 6 visits. First they will have a screening visit, followed by a baseline visit. Then they will have a visit 6 months later. Then they will have a visit 1, 2, and 3 years after the first visit. Visits will last 4 to 8 hours. Visits will include the following: Medical history and physical exam. Complete eye exam. Participants' eye pressure and ability to see letters on a vision chart will be tested. Their pupils will be dilated with eye drops. Pictures will be taken of the retina and the inside of the eye. Questions about participants' family history, especially the presence of eye disease. Visual field test. Participants will be seated in front of a large dome and asked to press a button when they see a light within the dome. Electroretinogram. Participants will sit in the dark with their eyes patched for 30 minutes. Then they will wear special contact lenses and watch flashing lights. Optical coherence tomography. Cross-sectional pictures will be taken of participants' retinas. Fundus autofluorescence. Blue light will be shone into participants eyes to assess the health of the retina....
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2028-07-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04591483
The ClinicalTrials.gov registry entry for NCT04591483 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stargardt-like Macular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT04591483 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04591483 about?
NCT04591483 is a clinical study titled "Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4". Background: STDG3 is an inherited eye disease. Currently there is no treatment for STDG3. Past studies of STDG3 have largely looked at members of large families at a single time point. Researchers want to learn more about the disease at an individual level. Objective: To understand the natural hi...
What is the current status of trial NCT04591483?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2022-04-19. Estimated completion is 2028-07-16.
What conditions does trial NCT04591483 study?
This clinical trial studies the following conditions: Stargardt-like Macular Dystrophy.
Who is sponsoring clinical trial NCT04591483?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04591483 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt-like Macular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.